STOCKS TELEGRAPH

Tag: NASDAQ: STSS

  • 3 Stocks That Could Make Headlines: Cardiol Therapeutics (CRDL), Sharps Technology (STSS), Kairos Pharma (KAPA)

    3 Stocks That Could Make Headlines: Cardiol Therapeutics (CRDL), Sharps Technology (STSS), Kairos Pharma (KAPA)

    The healthcare and biotechnology sectors continue to attract investor attention as companies advance clinical development programs, pursue strategic growth initiatives, and navigate evolving market conditions. With increasing focus on late-stage trials, commercialization potential, and financial performance, market participants remain closely attentive to emerging opportunities and developments shaping the industry landscape.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) continues to attract investor attention as it advances its lead cardiovascular therapy through late-stage clinical development while increasing visibility within the institutional investment community. For emerging biotech companies, maintaining strong communication with investors often becomes increasingly important as pivotal trial milestones approach.

    Market Momentum

    As of May 18, 2026, CRDL closed at $1.28, down 3.03%, with trading volume of 442,128 shares compared to an average volume of 689,763 shares. The company currently maintains a market capitalization of $147.548M and a beta of 0.43, reflecting relatively moderate volatility for a clinical-stage biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.35 suggests substantial upside potential tied to future clinical and regulatory milestones.

    Investor and Corporate Visibility

    Cardiol recently announced that management will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York on May 19, 2026. Participation in industry and investor conferences can provide important opportunities for biotech companies to discuss pipeline progress, clinical milestones, and long-term strategic priorities directly with institutional investors and healthcare-focused analysts.

    Late-Stage Clinical Progress

    The company continues advancing its Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis, with enrollment already surpassing 75% of participants. Earlier Phase II findings demonstrated reductions in pain, inflammation, and recurrence frequency, helping establish the clinical foundation supporting the ongoing pivotal study.

    Outlook

    With increasing investor engagement, continued late-stage clinical execution, and growing visibility within the biotech sector, Cardiol appears positioned to maintain market attention as it advances toward future development and commercialization milestones.

    Sharps Technology Inc (STSS)

    Sharps Technology Inc (NASDAQ: STSS) started the day on May 18, 2026, with a price decrease of -4.26% at $1.8. During the day, the stock rose to $1.87 and sank to $1.78. Taking a long-term approach, STSS posted a 52-week range of $1.41-$18.23.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 63.36%. Meanwhile, its Annual Earnings per share during the time was 63.36%.  This publicly-traded company’s shares outstanding now amount to $39.42 million, simultaneously with a float of $31.91 million. The organization now has a market capitalization of $76.18 million.

    Kairos Pharma Ltd (NYSEAMERICAN: KAPA)

    As of May 18, 2026, Kairos Pharma Ltd (NYSEAMERICAN: KAPA) started slowly as it slid -0.46% to $0.48. During the day, the stock rose to $0.49 and sank to $0.45. Taking a more long-term approach, KAPA posted a 52-week range of $0.40-$2.11.

    In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was -29.30%. Meanwhile, its Annual Earnings per share during the time were -29.30%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is -23.33%. This publicly-traded company’s shares outstanding now amount to $21.41 million, simultaneously with a float of $12.65 million. The organization now has a market capitalization of $10.27 million.

  • Sharps Technology (STSS) Sees Explosive After-Hours Surge Amid Uncertainty

    Sharps Technology, Inc. (NASDAQ: STSS) made waves on Wednesday with a notable 3.8% increase during regular trading hours. Yet, the real excitement unfolded after the closing bell, as the stock skyrocketed by an astonishing 50% in after-hours trading.

    This unexpected surge has left investors and market watchers buzzing, given the lack of any obvious news catalysts.

    Unprecedented Trading Volume

    The after-hours activity saw Sharps Technology’s trading volume soar to nearly 8.2 million shares. This figure is particularly striking when compared to its average trading volume of under 300,000 shares.

    The 27-fold increase underscores a massive surge in demand for the stock, likely driven by speculative buying rather than any concrete news. This kind of volume typically hints at significant interest and speculation, though it also raises questions about the sustainability of such a rally.

    The Company and Recent Developments

    Sharps Technology is a medical device and pharmaceutical packaging company that specializes in innovative drug delivery systems. Despite its ambitious focus on low-waste and ultra-low waste syringe technologies with both passive and active safety features, the company faces significant financial challenges. It has no revenue, no profit, and minimal cash reserves. Yet, Aegis Capital, a well-known investment banker, has maintained a $16 price target on the stock for over two years.

    Recently, Sharps Technology announced a renewed $188 million syringe deal with Nephron Pharmaceuticals. This agreement, contingent on Sharps raising $35 million to purchase the InjectEZ plant from Nephron, could be a transformative development. However, the company’s track record raises concerns. Sharps has missed several deadlines and continues to face production challenges, particularly with the Provensa syringe in Hungary.

    Potential for Profit-Taking

    The significant after-hours price movement, juxtaposed with Sharps Technology’s financial struggles and operational hurdles, has led to speculation about a potential profit-taking dip. While bullish investors are currently riding the momentum, the absence of solid news to support the surge suggests caution.

    The recent earnings report also adds to the uncertainty, with Sharps posting a larger-than-expected loss of -5 cents per share, missing analysts’ estimates of -4 cents, and reporting no revenue for the first quarter of 2024.

    Conclusion

    Sharps Technology’s dramatic after-hours surge highlights the volatile nature of speculative trading. With a history of missed deadlines and financial instability, the company faces significant hurdles despite the promising syringe deal with Nephron. Investors should remain vigilant, as the current enthusiasm may quickly turn to caution in the face of the company’s ongoing challenges.

  • STSS: Navigating Market Volatility and Strategic Alliances

    Sharps Technology, Inc. (NASDAQ: STSS), a prominent player in the medical device and pharmaceutical packaging industry, has recently experienced a tumultuous ride on the premarket session of the stock market.

    Specializing in innovative drug delivery systems, the company has been a key player in the development of low waste and ultra-low waste syringe technologies, incorporating both passive and active safety features.

    Market Dynamics and Speculation

    With a surprising 8% climb during regular trading hours, Sharps Technology, Inc. raised eyebrows in the market, and the intrigue only deepened with a subsequent 25% plunge in the premarket.

    The noteworthy 300K after-hours volume suggests that something substantial is afoot, intensifying speculations among investors. A persistent buzz surrounds the potential confirmation of a lucrative deal with Nephron, promising a guaranteed annual revenue of $40 million for the next decade.

    This significant windfall could pave the way for the company to settle its loan, secured for the acquisition of a $50 million facility from Nephron. This places Sharps in a unique position, transforming a $6 million company into one with a staggering $400 million deal, opening avenues for additional partnerships.

    Strategic Partnership and Expansion

    Sharps Technology’s strategic collaboration with Nephron, a pharmaceutical giant specializing in affordable generic inhalation solutions and pre-filled sterile syringes, has been a pivotal move. Nephron’s InjectEZ expansion project, supported by a substantial investment over the past two years, aligns with Sharps’ commitment to innovation and safety.

    The partnership focuses on research and development, reflecting the shared commitment to manufacturing excellence, customer support, and quality. Lou Kennedy, Nephron’s CEO, emphasized the excitement about the collaboration, foreseeing key solutions to healthcare challenges emerging from this partnership. Sharps, historically known for its low waste syringe technologies, anticipates expanding its product portfolio and making a significant impact on the specialized pre-fillable syringe and drug delivery systems market.

    Conclusion

    In the wake of these recent developments, Sharps Technology, Inc. stands at the forefront of a transformative period, poised to capitalize on strategic partnerships and innovative solutions in the ever-evolving healthcare landscape.

    The positive chatter and heightened investor enthusiasm underscore the potential for Sharps to not only solidify its market position but also to play a pivotal role in addressing pressing healthcare challenges.